CTLA4 and neoplasm: Recently the study of the immune system within the TME allowed to develop new treatments based on the targeting of inhibitory receptors present on tumor infiltrating leukocytes (CTLA-4, PD-1), and later on their ligands which are expressed by other immune cells as well as tumor cells (PD-L1) (10).